Stockscreener 앱 받기
0.7052
1.45%
0.0101
시간 외 거래:
.70
-0.0052
-0.74%
전일 마감가:
$0.6951
열려 있는:
$0.7
하루 거래량:
381.76K
Relative Volume:
0.64
시가총액:
$47.63M
수익:
-
순이익/손실:
$-81.22M
주가수익비율:
-0.2382
EPS:
-2.96
순현금흐름:
$-74.41M
1주 성능:
+10.15%
1개월 성능:
-3.42%
6개월 성능:
+0.84%
1년 성능:
-29.83%
1일 변동 폭
$0.70
$0.7189
1주일 범위
$0.6402
$0.7189
52주 변동 폭
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
명칭
Xilio Therapeutics Inc
전화
617-833-1027
주소
828 WINTER STREET, WALTHAM
XLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.7052 | 46.95M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | Leerink Partners | Outperform |
| 2022-12-21 | 개시 | Chardan Capital Markets | Buy |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
| 2021-11-16 | 개시 | Cowen | Outperform |
| 2021-11-16 | 개시 | Guggenheim | Buy |
| 2021-11-16 | 개시 | Morgan Stanley | Overweight |
| 2021-11-16 | 개시 | Raymond James | Outperform |
모두보기
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Xilio Therapeutics reports $35.8 million in proceeds from Series B warrant exercises - Investing.com Nigeria
Xilio Therapeutics Extends Cash Runway Into 2027 - TipRanks
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Decrease in Short Interest - Defense World
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.5% – What’s Next? - Defense World
Will Xilio Therapeutics Inc. stock reach all time highs in 20252025 Market Overview & High Accuracy Swing Trade Signals - bolumsonucanavari.com
Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 PreEarnings & Risk Managed Investment Strategies - Улправда
Is Xilio Therapeutics Inc. stock dividend yield sustainableWeekly Market Report & High Conviction Investment Ideas - Улправда
Is Xilio Therapeutics Inc. stock a defensive play in 2025July 2025 Sector Moves & Free Fast Gain Swing Trade Alerts - Улправда
Loss Report: Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 EndofMonth & High Win Rate Trade Alerts - Улправда
Why Xilio Therapeutics Inc. stock remains undervaluedJuly 2025 Reactions & High Win Rate Trade Tips - bolumsonucanavari.com
Why Xilio Therapeutics Inc. stock attracts high net worth investorsMarket Sentiment Report & AI Based Buy/Sell Signal Reports - Улправда
Is Xilio Therapeutics Inc. stock supported by strong fundamentalsProfit Target & High Conviction Investment Ideas - Улправда
Xilio Therapeutics Inc (XLO) looking to reclaim success with recent performance - setenews.com
Xilio Therapeutics Inc (XLO) can make a big difference with a little luck - setenews.com
Xilio Therapeutics, Inc. (XLO) -5.65% in After-hours: Slide Amid Routine Trading Conditions - Stocks Telegraph
Is Xilio Therapeutics Inc. stock trading at a premium valuationJuly 2025 Sentiment & Fast Gain Swing Alerts - Newser
Why Xilio Therapeutics Inc. stock is trending among retail traders2025 Price Action Summary & Expert Curated Trade Ideas - Newser
Can Xilio Therapeutics Stock Recover If Markets Fall? - Trefis
Recap Report: Why Xilio Therapeutics Inc. stock attracts high net worth investorsProduct Launch & High Accuracy Investment Signals - moha.gov.vn
Xilio Therapeutics announces pricing of $50 million public offering - MSN
Xilio Therapeutics Approves 2025 Stock Incentive Plan - MSN
[S-8] Xilio Therapeutics, Inc. Employee Benefit Plan Registration | XLO SEC FilingForm S-8 - Stock Titan
[Form 4] Xilio Therapeutics, Inc. Insider Trading Activity - Stock Titan
[8-K] Xilio Therapeutics, Inc. Reports Material Event | XLO SEC FilingForm 8-K - Stock Titan
AbbVie and Xilio partner for tumor-activated therapies - MSN
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates - MSN
Is Xilio Therapeutics Inc. stock a buy before product launchesJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
How institutional buying supports Xilio Therapeutics Inc. stockMarket Performance Report & High Accuracy Trade Alerts - newser.com
Is Xilio Therapeutics Inc. stock resilient to inflationWeekly Trade Report & Low Risk High Reward Trade Ideas - newser.com
Is Xilio Therapeutics Inc a good long term investmentFundamental Stock Analysis & Free Technical Analysis and Insights - earlytimes.in
Can Samtex Fashions Limited Outperform Index Funds Over the Next 5 YearsEmerging Market Stocks & Free Rapid Profit Acceleration - earlytimes.in
Can GSM Foils Limited Sustain EPS Growth Under Competitive PressureEquity Performance Review & Low Risk Trading Portfolio - earlytimes.in
Is ACRS a good long-term investment? - earlytimes.in
Tick level data insight on Xilio Therapeutics Inc. volatilityGlobal Markets & Stock Timing and Entry Methods - newser.com
How Xilio Therapeutics Inc. stock compares to market leadersWeekly Gains Report & High Accuracy Trade Signal Alerts - newser.com
Why Xilio Therapeutics Inc. stock remains on watchlists2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
Xilio Therapeutics Reports Revenue Growth Amidst Challenges - MSN
Why Xilio Therapeutics Inc. stock is in analyst buy zoneTrade Exit Summary & Verified Entry Point Signals - newser.com
How geopolitical tensions affect Xilio Therapeutics Inc. stock2025 Macro Impact & Daily Stock Momentum Reports - newser.com
Is Xilio Therapeutics Inc. stock safe for conservative investorsJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Is it too late to sell Xilio Therapeutics Inc.2025 Market Trends & AI Forecasted Entry and Exit Points - newser.com
Is it time to cut losses on Xilio Therapeutics Inc.Portfolio Value Report & Daily Technical Stock Forecast Reports - newser.com
Published on: 2025-11-19 00:08:23 - newser.com
Xilio Therapeutics Inc (XLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):